Allergen immunotherapy in the BRIT Registry
No Thumbnail Available
Authors
Baigel R.
Villa L.P.
Maslovskaya O.O.
Smith M.
Achunche S.
Dawson T.
Gourgey R.
Kelly M.
Khan S.
Marriage D.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Objectives: Allergen Immunotherapy (AIT) is used for disease modification of severe rhinoconjunctivitis and can be given by sublingual (SLIT) and subcutaneous routes (SCIT). The BRIT registry records data on participants receiving AIT and we report the current state of the registry to evaluate the real-world use and demographic patterns of allergen immunotherapy (AIT) for allergic rhinitis and associated conditions, using data from BRIT (BSACI Registry for Immunotherapy). Method(s): Retrospective data from the registry showed 2,382 participants received 2812 treatments via sublingual (SLIT) or subcutaneous (SCIT) routes for allergic rhinitis, allergic conjunctivitis asthma, or related allergic conditions. Participants who were missing key variables were excluded. Allergic sensitisation was confirmed using skin prick tests, specific IgE, or component-specific IgE. Asthma status (BTS/SIGN guideline steps), and allergen sensitisation (mono-vs polysensitised) were included in subgroup analyses. Result(s): Demographics: 59% (n = 1410) of the participants were children and 41% (n = 972) were adults. Seasonal (57.1%) or perennial (21.7%) allergic rhino-conjunctivitis was the most common 1041 condition. 31.4% had comorbid asthma; however, asthma severity data were missing in 7.1% of records. Sensitisation: 53.1% (1266) were mono-sensitised whereas 46.9% (1116) were poly-sensitised. Grass pollen was the most common allergen (75.7%), followed by house dust mite (38.9%), tree pollen (35.3%), animal dander (14.5%) and mould spores (3.7%). Treatment: 66% of the registered participants received SLIT 28% received SCIT. SLIT was more frequently used in children and for seasonal allergens. 74% were receiving immunotherapy while 18.8% had stopped treatment. Conclusion(s): BRIT contains a large cohort of AIT participants for both adults and children and is representative of all treatments provided in the UK. These findings reinforce the value of real-world registries in evaluating the longitudinal impact of immunotherapy and highlights the values of participation in registry data collection for benchmarking and quality of services.
Description
Citation
Publisher
License
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology